Today's Top Biotech Stocks to Watch: Johnson & Johnson and Sarepta Therapeutics

Today's top stories in biotech and health care.

Jul 11, 2014 at 8:48AM


Let's take a look at today's top stories in biotech and health care. Keep an eye out for Johnson & Johnson (NYSE:JNJ) and Sarepta Therapeutics (NASDAQ:SRPT)

Analysts are optimistic about Johnson & Johnson's second quarter earnings 
With J&J set to reveal second quarter earnings next Tuesday, July 15, Wall Street analysts are predicting that the company will beat consensus earnings per share of $1.54, fueled by better than expected pharma sales. In the first-quarter, J&J surprised the Street with stellar sales of its hepatitis C drug, Olysio, which helped propel pharmaceutical growth by 10.8% year over year and compensate for weakness in its other business segments.  

While I think the analysts are on target with their optimistic expectations for the second quarter, J&J does have major competition to worry about for some of its key drugs like Zytiga and Olysio. AbbVie's hepatitis C drug, for instance, should gain approval later this year and poses a major threat to Olysio's commercial performance going forward.

In short, I think J&J's bull run is close to coming to an end, despite what looks to be a strong second quarter. And thus far, the market also doesn't appear to be impressed with these positive comments, given that J&J's shares remain unchanged in premarket trading this morning.   

Will Sarepta rebound today?
Sarepta saw a strong sell-off yesterday following a 144-week clinical update for its open-label extension study of its exon-skipping Duchenne muscular dystrophy, or DMD, drug eteplirsen. Specifically, patients participating in the open-label portion of the study declined by about 8.5% on average from baseline in walking ability, which was the biggest decrease in walking performance observed thus far. 

Although shares rebounded late in the session, they still ended the day down nearly 13%. Shares are presently down over 1% in premarket trading on moderate volume. 

In a note to investors, Needham suggested that the sell off was unwarranted and caused primarily by misleading article that appeared in The Wall Street Journal. By the same token, we saw a number of downgrades by other firms for Sarepta yesterday based on this latest clinical update.

Looking ahead, the main concern is that eteplirsen will turn out to be ineffective at improving walking ability over the long term in DMD patients, perhaps even lowering its chances of gaining a regulatory approval. While the jury is still out on eteplirsen's regulatory risk following this latest clinical update, Sarepta should certainly be interesting to watch today as the bulls and bears battle it out.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


George Budwell owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers